Trial · NCT03370718
Cabozantinib in Treating Patients With Locally Advanced or Metastatic Unresectable Adrenocortical Carcinoma
NCT03370718, Phase 2, Completed, M.D. Anderson Cancer Center; results first posted 2024-12-10
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Cabozantinib in Treating Patients With Locally Advanced or Metastatic Unresectable Adrenocortical Carcinoma. Trials, record NCT03370718. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT03370718
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Cabozantinib in Treating Patients With Locally Advanced or Metastatic Unresectable Adrenocortical Carcinoma
- NCT number
- NCT03370718
- Status
- Completed
- Phases
- Phase 2
- Enrollment
- 18 participants, actual
- Lead sponsor
- M.D. Anderson Cancer Center
- Conditions
- Metastatic Carcinoma in the Adrenal Cortex, Stage III Adrenal Cortex Carcinoma AJCC v8, Stage IV Adrenal Cortex Carcinoma AJCC v8, Unresectable Adrenal Cortex Carcinoma
- Interventions
- Cabozantinib, Pharmacogenomic Study, Pharmacokinetic Study
- First posted
- 2017-12-12
- Last updated
- 2024-12-10
- Results first posted
- 2024-12-10
Source ClinicalTrials.gov
Registered outcomes1
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Progression-free Survival (PFS) as Defined by Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 Criteria | At 4 months | PFS rates will be monitored simultaneously using the Bayesian approach of Thall, Simon, Esty as extended by Thall and Sung. PFS is defined as no disease progression or death within the first 4 months of the proposed treatment. |
Source ClinicalTrials.gov
Outcomes1
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
| Type | Outcome | Time frame | Population | Units | Measured as |
|---|---|---|---|---|---|
| PRIMARY | Progression-free Survival (PFS) as Defined by Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 Criteria | At 4 months | precentage of participants | NUMBER |
Source ClinicalTrials.gov
Results by group1
Each measurement the trial posted, group by group, in the words and numbers it posted.
| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Progression-free Survival (PFS) as Defined by Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 Criteria | Cabozantinib | 72.2 | 95% Confidence Interval 46.5 to 90.3 | precentage of participants |
Source ClinicalTrials.gov
Participant flow3
How many started, completed or left each group, period by period.
| Period | Milestone | Group | Participants | Units counted |
|---|---|---|---|---|
| Overall Study | STARTED | Cabozantinib | 18 | |
| Overall Study | COMPLETED | Cabozantinib | 17 | |
| Overall Study | NOT COMPLETED | Cabozantinib | 1 |
Source ClinicalTrials.gov
Adverse events127
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
| Type | Event | Organ system | Group | Affected | At risk | Events |
|---|---|---|---|---|---|---|
| other | Abdominal pain | Gastrointestinal disorders | Cabozantinib | 7 | 18 | |
| other | Acne | Skin and subcutaneous tissue disorders | Cabozantinib | 1 | 18 | |
| other | Acute respiratory failure | Respiratory, thoracic and mediastinal disorders | Cabozantinib | 1 | 18 | |
| other | Alanine aminotransferase increased | Investigations | Cabozantinib | 14 | 18 | |
| other | Alkaline phosphatase increased | Investigations | Cabozantinib | 11 | 18 | |
| other | Anemia | Blood and lymphatic system disorders | Cabozantinib | 7 | 18 | |
| other | Anorexia | Metabolism and nutrition disorders | Cabozantinib | 6 | 18 | |
| other | Arthralgia | Musculoskeletal and connective tissue disorders | Cabozantinib | 1 | 18 | |
| other | Aspartate aminotransferase increased | Investigations | Cabozantinib | 13 | 18 | |
| other | Back pain | Musculoskeletal and connective tissue disorders | Cabozantinib | 3 | 18 |
1 to 10 of 127Source ClinicalTrials.gov
See all 127 adverse eventsAdverse event totals3
The totals the trial posted for each group.
| Total | Group | Affected | At risk |
|---|---|---|---|
| Total, all-cause mortality | Cabozantinib | 1 | 18 |
| Total, other adverse events | Cabozantinib | 18 | 18 |
| Total, serious adverse events | Cabozantinib | 0 | 18 |
Source ClinicalTrials.gov
Papers1
The papers the trial lists on ClinicalTrials.gov.
| PMID | Listed as |
|---|---|
| 38608694 | DERIVED |
Source PubMed
Grants1
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
| Project | Title | Principal investigators | Organization | Funder | Fiscal years |
|---|---|---|---|---|---|
| P30CA016672 | The University of Texas MD Anderson Cancer Center Support Grant (CCSG) | KOONG, ALBERT | UNIVERSITY OF TX MD ANDERSON CAN CTR | NATIONAL CANCER INSTITUTE | 1985 to 2026 |
Source NIH RePORTER
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT03370718
GET https://conductscience.org/api/trials/v1/NCT03370718/events?page=2